Discontinued — last reported Q3 '21
Amgen Finite-Lived Intangible Assets - Expected Amortization Expense (Year One) decreased by 55.0% to $900.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 80.0%, from $4.50B to $900.00M. This is a positive signal — lower values indicate better performance for this metric.
High amortization expenses reduce reported net income, though they are non-cash charges that do not impact operating cash flow.
This is the projected expense for the upcoming year related to the systematic write-down of finite-lived intangible asse...
Used to reconcile GAAP earnings with cash-based performance metrics across companies with heavy M&A activity.
finite_lived_intangible_assets_amortization_year_1| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.20B | $2.20B | $2.40B | $2.40B | $2.50B | $2.70B | $2.70B | $2.70B | $4.50B | $4.50B | $4.50B | $3.10B | $2.00B | $900.00M |
| QoQ Change | — | +0.0% | +9.1% | +0.0% | +4.2% | +8.0% | +0.0% | +0.0% | +66.7% | +0.0% | +0.0% | -31.1% | -35.5% | -55.0% |
| YoY Change | — | — | — | +9.1% | +13.6% | +12.5% | +12.5% | +8.0% | +66.7% | +66.7% | +66.7% | -31.1% | -55.6% | -80.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.